Defiance Leveraged Long +Income HIMS ETF

Kelly Services-B

Liminatus Pharma

Pro Ultrshrt Silver

UTime

GraniteShares 2x Short MSTR Daily ETF

Defiance Daily Target 2X Short MSTR ETF

T-REX 2X Inverse MSTR Daily Target ETF

Defiance Daily Target 2X Short QBTS ETF

TruGolf

C3is

NVOX

HIMZ

HIMS

HIMY

The FDA plans to take action against companies marketing illegal copycat drugs that mimic FDA-approved products. Commissioner Marty Makary highlighted concerns over Hims and Hers Health's unapproved $49 version of Novo Nordisk's Wegovy weight-loss pill, emphasizing the lack of verified quality and safety for non-approved drugs. Following the announcement, Hims' shares fell by 4.7% in after-hours trading.

fidelity

VG Health

iShares US Medical Devices

iShares US Healthcare Providers

Defiance Daily Target 2X Long NVO ETF

Defiance Daily Target 2X Long HIMS ETF

SPDR S&P Health

iShares Global Healthcare

Hims & Hers Health

Health Care Select Sector SPDR

SPDR S&P Health Equip

Novo Nordisk AS

iShares US Pharma

FDA to take action on companies marketing 'illegal copycat drugs', FDA chief says

Telemedicine company Hims launched a generic version, priced at $99 per month, significantly lower than the brand-name drug at $149. Novo Nordisk accused it of "illegal compounding" and threatened to sue, claiming the generic lacks proprietary protection technology and cannot be effectively absorbed. Hims argued that it uses a different formula. As a result, Novo Nordisk's stock price plummeted over 8%

- Novo Nordisk faced an unexpected market challenge with the launch of Hims & Hers Health’s generic version of its obesity drug Wegovy, priced significantly lower.  
- The introduction of the generic version sparked debates over drug patent protection and regulatory frameworks, with Novo Nordisk expressing intentions to protect its intellectual property legally.  
- As a result of this news, Novo Nordisk's stock fell over 8%, while competitors like Eli Lilly also experienced declines, indicating heightened investor concerns regarding market position and growth expectations.

Wallstreetcn

Novo Nordisk plummeted 8%, as the new weight loss pill faced "knockoffs" right after its launch, with telemedicine company Hims introducing a $49 generic version

LLYX

ELIL

Healthcare companies experienced a decline due to concerns over an obesity-drug price war. Novo Nordisk's shares fell after it accused Hims & Hers of illegal practices, while Hims & Hers announced a low introductory price for Wegovy copies. Eli Lilly's shares also dropped despite previous gains. Cigna's shares rose due to growth in its pharmacy-benefit unit, while UnitedHealth Group and other insurers saw declines. Cardinal Health's shares surged after raising its profit forecast due to strong demand.

marketscreener

Leverage Shares 2X Long UNH Daily ETF

Cigna

Defiance Daily Target 2X Long LLY ETF

VanEck Pharmaceutical ETF

Cardinal Health

Invesco Pharmaceuticals ETF

Eli Lilly

Unitedhealth

SPDR Pharmac

Direxion Daily LLY Bull 2X Shares

Health Care Down Amid Concerns About Obesity-Drug Price War -- Health Care Roundup

Hims & Hers launches Wegovy knockoff pill, Novo Nordisk vows to sue

Barchart Option

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

Invesco Nasdaq Biotechnology ETF

VanEck Biotech ETF

iShares Biotechnology ETF

Ark Genomic Revolution ETF

Hims & Hers launches Wegovy knockoff pill, Novo Nordisk vows to sue

Market Update: The S&P 500 E-Mini Futures are down 1.32% year-to-date, with price action fluctuating between $6,800 and $7,050. Significant sell-offs have found buyers, but if sellers maintain control, targets may drop to $6,700 and $6,610. Key stocks to watch in February include Alphabet (GOOGL), Amazon (AMZN), Reddit (RDDT), Robinhood (HOOD), Lyft (LYFT), Shopify (SHOP), Coinbase (COIN), Hims & Hers (HIMS), Workday (WDAY), and NVIDIA (NVDA), with varying year-to-date performance and implied volatility ratings.

- The S&P 500 E-Mini Futures are down 1.32% year-to-date, with price action hovering around $6,800 and $7,050, indicating market hesitancy.  
- Significant buying has occurred during sell-offs, but if sellers maintain control in February, targets may hit $6,700 and $6,610.  
- Key stocks to watch include Alphabet, Amazon, and Robinhood, all showing varied year-to-date performance and implied volatility ratings.

Tasty Live

S&P 500

Coinbase

Leverage Shares 2X Long HOOD Daily ETF

Direxion Daily GOOGL Bull 2X Shares

LYFT

Defiance Daily Target 2X Long HOOD ETF

Robinhood

Workday

Amazon

Alphabet - C

Top 10 Stocks to Watch: February 2026

INSTANT VIEW-Hims and Hers Health's compounded Wegovy pill offering fuels market jitters

INSTANT VIEW-Hims and Hers Health's compounded Wegovy pill offering fuels market jitters

Bitcoin has fallen below the critical $67,000 support level, raising concerns about further declines amid macroeconomic pressures. Hims & Hers has initiated a price war in weight-loss drugs by offering a compounded oral semaglutide pill for $49, challenging Big Pharma's pricing. Meanwhile, Saudia Airlines is in talks for a significant order of at least 150 jets, potentially reshaping the aviation market. Commodities, including gold and silver, are under pressure, with gold trading around $4,926 and silver dropping 13% to approximately $73.60.

Invezz

Hut 8 Mining

American Bitcoin

Riot Platforms

Grayscale Bitcoin Trust BTC - ETF

Mara

CoinShares Bitcoin ETF

ProShares Bitcoin Strategy ETF

ARK 21Shares Bitcoin ETF

Amplify Transform Data Sharing ETF

Bitwise Bitcoin ETF

Franklin Bitcoin ETF

Valkyrie Bitcoin and Ether Strategy ETF

Leverage Shares 2X Long COIN Daily ETF

GraniteShares 2x Short COIN Daily ETF

GraniteShares 2x Long MARA Daily ETF

WisdomTree Bitcoin Fund

VanEck Bitcoin ETF

iShares Bitcoin Trust ETF

GraniteShares 2x Long COIN Daily ETF

Fidelity Wise Origin Bitcoin Fund - ETF

Invesco Galaxy Bitcoin ETF

Evening digest: Bitcoin crashes, weight-loss drug price war, Saudia’s fleet expansion

Health care stocks experienced a decline on Thursday, with the NYSE Health Care Index down 0.4% and the State Street Health Care Select Sector SPDR ETF easing 0.3%. Novo Nordisk plans legal action against Hims & Hers over marketing compounded Wegovy pills, leading to a 7% drop in Novo shares and a 5% drop in Hims & Hers. Eikon Therapeutics fell 10% after its Nasdaq debut, while Bristol-Myers Squibb rose 3.5% following strong Q4 earnings and a positive 2026 outlook.

ProShares Ultra Health Care ETF

iShares US Healthcare

Sector Update: Health Care Stocks Softer Thursday Afternoon

Novo Nordisk's shares fell sharply after Hims & Hers Health launched a $49 copycat version of Wegovy, further impacting the company's stock, which had already been struggling due to a disappointing sales outlook. The stock dropped below 300 kroner, marking a significant decline. Novo's recent partnership termination with HIMS and increasing competition from Eli Lilly's Zepbound add to the challenges in the GLP-1 market. Analysts had previously suggested buying the dip, but the outlook remains tough for Novo.

Talkmarkets

$49 Wegovy Copycat Pill Sparks Selloff In Novo Shares

The "affordable weight loss drug" supplier Hims & Hers fell 1.4%, having risen as much as 14% earlier in the day

Hims & Hers has a GLP-1 weight loss pill -- and it's the cheapest one out there.

Direxion S&P Biotech Bear 3X

Why Eli Lilly stock just dropped

ELIS

Eli Lilly's stock (LLY) fell 6% following news that Hims & Hers Health (HIMS) is selling a $49 weight-loss pill, Wegovy, made by Novo Nordisk (NVO), which is priced significantly lower than Novo Nordisk's $149. In contrast, HIMS stock rose 10%. Hims & Hers claims their product is a "personalized copy" of Wegovy, while Novo Nordisk seeks to block sales. Eli Lilly is expected to launch a competing oral weight-loss pill pending FDA approval.

Tip Ranks

Direxion Daily LLY Bear 1X Shares

Eli Lilly Stock (LLY) Falls on News Hims & Hers Is Selling a $49 Weight-Loss Pill

All three major US stock indexes fell as job cuts surged to the highest January total since 2009. Alphabet reported Q4 earnings of $2.82 per share, exceeding estimates, but shares dropped 2.8%. Rio Tinto ended merger talks with Glencore, leading to a 4.9% decline in its shares. Hims & Hers Health shares rose 3.5% after announcing a new product, while Peloton shares plummeted 22.6% following disappointing earnings. Shell's Q4 earnings fell short of expectations, and shares dropped 4.5%.

Defiance Leveraged Long +Income HIMS ETF(HIMY.US)

FDA to take action on companies marketing 'illegal copycat drugs', FDA chief says

Novo Nordisk plummeted 8%, as the new weight loss pill faced "knockoffs" right after its launch, with telemedicine company Hims introducing a $49 generic version

Health Care Down Amid Concerns About Obesity-Drug Price War -- Health Care Roundup

Hims & Hers launches Wegovy knockoff pill, Novo Nordisk vows to sue

Top 10 Stocks to Watch: February 2026